Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novartis AG Common Stock (NY:NVS)

109.59 +1.13 (+1.04%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
45 46 Next >
Malignant Pleural Effusion Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche Holdings AG, Bristol Myers Squibb, Novartis, Merck
Via AB Newswire
Exposures Product Safety
Pulmonary Sarcoidosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Novartis, aTyr Pharma, SarcoMed USA, Actelion, Bellerophon, Corbus Pharma
Via AB Newswire
Exposures Product Safety
Multiple Sclerosis Market | Companies – Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, expected to boost the market
Via AB Newswire
Weight Loss Drugs Market May Set Epic Growth Story : Abbott Laboratories, Teva, Novartis
Stay up-to-date with Weight Loss Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Porphyria Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies – Alynylm Pharmaceuticals, Novartis Pharmaceuticals, Cycle Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals
Via AB Newswire
Interstitial Lung Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Roche, Novartis, AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharma
Via AB Newswire
Exposures Product Safety
Multiple Sclerosis Market expected to rise | Companies – Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, Biogen
Via AB Newswire
Multiple myeloma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Alliance Foundation Trials, LLC, Celgene
Via AB Newswire
Exposures Product Safety
Food Allergy Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Vedanta Biosciences, Aravax, Regeneron, DBV Technologies, Novartis, Genentech
Via AB Newswire
Exposures Product Safety
Aortic Stenosis Market to witness growth by 2032, estimates DelveInsight | Boston Scientific Corporation, Medtronic plc, Novartis, Boston Scientific Corporation, Abbott, LivaNova, Edward Lifescience
Via AB Newswire
Cold Agglutinin Disease Market expected to rise | Companies – Sanofi, Bioverativ, Sobi, Apellis Pharmaceuticals, Novartis, Incyte Corporation, expected to drive market
Via AB Newswire
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation
Mizuho initiated coverage on Terns Pharmaceuticals Inc (NASDAQ: TERN) with a Buying rating and price target of $16,  
Via Benzinga
Chronic Pain Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Biosplice Therapeutics, Sorrento Therapeutics, Amplo Pharma Novartis, Eli Lilly
Via AB Newswire
Cerebral Aneurysm Treatment Market, Epidemiology, Therapies, FDA Approval, Companies and Market forecast by DelveInsight | Biogen, Pfizer, Roche, Merck, Novartis, Sanofi, Teva Pharmaceutical
Via AB Newswire
Exposures Product Safety
Refractory Acute Myeloid Leukemia Market to witness growth by 2032, estimates DelveInsight | Pfizer, Merck, Novartis, Astellas, Amgen, Janssen, Kartos, Cullinan Oncology, Meryx
Via AB Newswire
Osteoarthritis Market to witness growth by 2032, estimates DelveInsight | Novartis, Ampio Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis
Via AB Newswire
Eosinophilic Gastroenteritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | Novartis, Allakos, AstraZeneca, Pfizer, Regeneron, Celgene
Via AB Newswire
Eczema Market to witness growth by 2032, estimates DelveInsight | Sanofi S.A., Power Life Sciences, Encore Dermatology, AbbVie, Kymab Limited, F. Hoffmann-La Roche AG, Novartis, Regeneron Pharma
Via AB Newswire
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market to Accelerate Substantially During the Forecast Period (2023-2032) – DelveInsight | GlycoMimetics, Servier, Novartis, ImmunoGen, Ascentage
Via AB Newswire
Diabetic Retinopathy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Kodiak Sciences, Novartis, Regenxbio Inc., Bayer, RemeGen, OcuTerra Therapeutics
Via AB Newswire
Exposures Product Safety
Non-Small Cell Lung Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, AstraZeneca, Bristol-Myers, Roche
Via AB Newswire
Exposures Product Safety
Neuroblastoma Market to witness growth by 2032, estimates DelveInsight | Aptorum, Athenex, Eli Lilly, Clarity Pharmaceuticals, Y-mAbs Therapeutics Inc, Novartis AG, Bristol-Myers Squibb, Roche
Via AB Newswire
Pancreatic Cancer Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | ERYtech, FibroGen, Novartis, Eleison, Panbela, Redx Pharma, Immodulon, GSK, Merck
Via AB Newswire
Nasal Polyposis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies – AstraZeneca, Allakos, Idorsia Pharmaceuticals, Novartis, Regeneron Pharma, Sanofi, Amgen and others
Via AB Newswire
Nasopharyngeal Cancer Pipeline, NDA Approvals, Clinical Trials, and Emerging Drugs (2023) | Companies – Novartis, Innovent Biologics, BeiGene, Merck, Tessa Therapeutics, and Others
Via AB Newswire
Why Shares of Vera Therapeutics Jumped Tuesday
The company announced early phase 2 trials information regarding its lead therapy. 
Via The Motley Fool
Vernal Keratoconjunctivitis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Santen, Novartis, Senju Pharma, Allakos, Astellas, Akari Therapeutics
Via AB Newswire
Type 1 Diabetes Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest Drug Approvals, Clinical Trials, and Treatment Outlook | Novartis, Histogen, Vertex Pharma
Via AB Newswire
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.